Angiotensin-neprilysin inhibition in acute decompensated heart failure
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS: We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure at 129 sites in the United States. After hemodynamic stabilization, patients were randomly assigned to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or enalapril (target dose, 10 mg twice daily). The primary efficacy outcome was the time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8. Key safety outcomes were the rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema. RESULTS: Of the 881 patients who underwent randomization, 440 were assigned to receive sacubitril-valsartan and 441 to receive enalapril. The time-averaged reduction in the NT-proBNP concentration was significantly greater in the sacubitril-valsartan group than in the enalapril group; the ratio of the geometric mean of values obtained at weeks 4 and 8 to the baseline value was 0.53 in the sacubitril-valsartan group as compared with 0.75 in the enalapril group (percent change, -46.7% vs. -25.3%; ratio of change with sacubitril-valsartan vs. enalapril, 0.71; 95% confidence interval [CI], 0.63 to 0.81; P<0.001). The greater reduction in the NT-proBNP concentration with sacubitril-valsartan than with enalapril was evident as early as week 1 (ratio of change, 0.76; 95% CI, 0.69 to 0.85). The rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. CONCLUSIONS: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy. Rates of worsening renal function, hyperkalemia, symptomatic hypotension, and angioedema did not differ significantly between the two groups. (Funded by Novartis; PIONEER-HF ClinicalTrials.gov number, NCT02554890 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, one-third of patients enrolled did not have a history of HF and just more than half had no previous ACEI or ARB use.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In-hospital initiation of sacubitril-valsartan resulted in a significantly greater proportional reduction in NT-proBNP compared with enalapril at weeks 4 and from baseline (mean time-averaged change in NT-proBNP, −46.7% vs 25.3%).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“This change was consistent across all subgroups, including those without previous HF and those who were RASi-naive.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
In the citing paper
“In the PIONEER-HF study it was noted that in patients admitted with acute decompensated HF and reduced ejection fraction, 65% had a history of HF but only 10% were receiving an MRA at the time of admission.8”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [8]
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
The Global Health and Economic Burden of Hospitalizations for Heart Failure
Ambrosy, A. P., Fonarow, G. C., Butler, J., Chioncel, O., Greene, S. J., Vaduganathan, M., Nodari, S., Lam, C. S. P., Sato, N., Shah, A. N., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.053 · Cited by 2,046
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Self-citationAmbrosy, A. P., Mentz, R. J., Fiuzat, M., Cleland, J. G. F., Greene, S. J., O’Connor, C. M., Teerlink, J. R., Zannad, F. M., & Solomon, S. D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1159 · Cited by 57
Self-citation
Cited by
Items 701–800 of 999
Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis
Luo, L., Xu, Y., Tang, K., Wu, J., Li, D., Ran, J., Zhang, L., Wang, D., Zhao, D., Yu, M., et al. (2022) · Medicine · doi:10.1097/md.0000000000029415 · Cited by 5
Frühe Implementierung der „Fantastic four“ bei Herzinsuffizienz mit reduzierter Ejektionsfraktion
Soltani, S., Böhm, M., Frey, N., Eden, M., Abdin, A., & Bauersachs, J. K. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1760-3843 · Cited by 4
Rapid recommendations: Updates from 2021 guidelines: part 1
O’Toole, D. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809664 · Cited by 3
Loomba, R. S., Ikeda, N., Dorsey, V., Yousaf, F., & Nelson-McMillan, K. L. (2023) · Pediatric Cardiology · doi:10.1007/s00246-023-03138-5 · Cited by 7
Ma, X., Iyer, S. R., Ma, X., Reginauld, S., Chen, Y., Pan, S., Zheng, Y., Moroni, D., Yu, Y., Zhang, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108547 · Cited by 5
Nessler, J., Krawczyk, K., Leszek, P., Rubiś, P., Rozentryt, P., Gackowski, A., Pawlak, A., Straburzyńska‐Migaj, E., Jankowska, E. A., Brzęk, A., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0163 · Cited by 8
Defining a Path Toward Improved Heart Failure Care
Desai, N. R., & Clark, K. A. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89418 · Cited by 4
Wussler, D. N., Belkin, M., Maeder, M. T., Walter, J. E., Shrestha, S., Kupska, K., Stierli, M., Flores, D., Kozhuharov, N., Gualandro, D. M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3065 · Cited by 3
Sheehan, M. M., Sokoloff, L. J., & Reza, N. (2024) · Cardiology Clinics · doi:10.1016/j.ccl.2024.02.005 · Cited by 14
Chen, D., Chen, C., Lee, C., Tseng, C., Chen, S., Chang, S., Chen, T., Chu, P., Hsieh, C., Wen, M., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14761 · Cited by 3
Christensen, M. K., Hyldgård, V. B., Madelaire, C., Pedersen, A. K., Møller, J. E., & Søgaard, R. (2025) · Heart · doi:10.1136/heartjnl-2024-325562 · Cited by 4
Pereira, N. L., Desai, V. K., & Jaffe, A. S. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1451 · Cited by 4
Filling the gaps in guideline-directed care
Betz, C. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88672 · Cited by 5
Holm, N., Bromage, D. I., Cannata, A. N., DeCourcey, J., Bhatti, P., Huang, M., & McDonagh, T. A. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001268 · Cited by 4
Barry, A. R. (2022) · CJC Open · doi:10.1016/j.cjco.2022.06.007 · Cited by 4
Chen, Y., He, Q., Mo, D., Chen, L., Lu, J.-L., Li, R.-X., & Huang, J. (2022) · Medicine · doi:10.1097/md.0000000000030904 · Cited by 4
Batchelor, R., Tie, E. N., Romero, L., Hopper, I., & Kaye, D. M. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.11.001 · Cited by 7
Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials
Zheng, S., Zhang, Y., Gu, L., Ma, K., Wang, X., Hou, Y., Zhang, F., & Gao, M. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001379 · Cited by 6
Straburzyńska‐Migaj, E., Dudek, M., Kałużna‐Oleksy, M., Kolasa, J., Nessler, J., Ptaszyńska‐Kopczyńska, K., Rostoff, P., & Lelonek, M. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16410 · Cited by 4
Maia, I. S., Marcadenti, A., Veiga, V. C., Miranda, T. A., Gomes, S. P. C., Carollo, M. B. D. S., Negrelli, K. L., Gomes, J. O., Tramujas, L., de Abreu-Silva, E. O., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100466 · Cited by 6
Yu, X., Yan, H., Zhu, Z., Zhang, W., Liu, B., Ma, M., Zhang, X., Wei, N., Wang, J., & Liu, F. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01253-y · Cited by 4
Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
Ryazanov, A. S., Ших, Е. В., Владимировна, М. М., & Kudryavtsev, A. A. (2023) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2023e12616 · Cited by 4
Chun, K., Oh, J., Lee, C. J., Park, J. J., Lee, S. E., Kim, M., Cho, H., Choi, J., Lee, H., Hwang, K., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101504 · Cited by 6
Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure
Cuthbert, J. J., Brown, O. I., Pellicori, P., Dobbs, K., Bulemfu, J., Kazmi, S., Sokoreli, I., Pauws, S. C., Riistama, J. M., Cleland, J. G. F., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14638 · Cited by 4
Acute heart failure – an EFIM guideline critical appraisal and adaptation for internists
Kokorin, K. V. A., Franco, Á. G., Cittadini, A., Kalējs, O., Larina, V. N., Marra, A. M., Medrano, F. J., Monhart, Z., Morbidoni, L., Pimenta, J. M., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.02.028 · Cited by 6
Strategies for the Management of Cardiorenal Syndrome in the Acute Hospital Setting
Chandramohan, D., Simhadri, P. K., Jena, N. K., & Palleti, S. K. (2024) · Hearts · doi:10.3390/hearts5030024 · Cited by 6
Implementing medical therapy during worsening heart failure
Bhatt, A. S., & Vaduganathan, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae566 · Cited by 4
Use of sacubitril/valsartan in Marfan syndrome–related cardiomyopathy: The first case report
Spoto, S., Valeriani, E., Locorriere, L., Anguissola, G. B., Pantano, A. L., Terracciani, F., Bono, M. C., Costantino, S., Ciccozzi, M., & Angeletti, S. (2019) · Medicine · doi:10.1097/md.0000000000017978 · Cited by 4
Consensus on basic conduct during the hospital admission of patients with acute heart failure
Rodríguez, J. M. F., Casado, J., Formiga, F., Franco, Á. G., Arévalo‐Lorido, J. C., Beltrán, M., González, J., Llàcer, P., Manzano, L., Morales‐Rull, J. L., et al. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.01.010 · Cited by 4
Angiotensin Receptor Neprilysin Inhibitors—2019 Update
Chalikias, G. K., & Tziakas, D. N. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07015-8 · Cited by 4
New pharmacotherapy for heart failure with reduced ejection fraction
Sotirakos, S., Wheen, P., Spiers, P., & Armstrong, R. L. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1784007 · Cited by 4
Lupi, A., Ariotti, S., Pace, D. D., Ferrari, I., Bertuol, S., Monti, L., Guasti, L., Gaudio, G. V., & Campana, C. (2021) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468211010706 · Cited by 4
ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
Tano, G. D., Lenarda, A. D., Iacoviello, M., Oliva, F. G., Urbinati, S., Aspromonte, N., Cipriani, M., Caldarola, P., Murrone, A., Gulizia, M. M., et al. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab078 · Cited by 5
Repetitive Therapie mit Levosimendan reduziert NT-proBNP und verbessert NYHA-Klasse: Ein Fallbericht
Wechsler, M., & Schwinger, R. H. G. (2022) · Aktuelle Kardiologie · doi:10.1055/a-1799-7077 · Cited by 4
Inpatient Initiation of Sacubitril/Valsartan
Chilbert, M. R., Rogers, K. C., Ciriello, D. N., Rovelli, R. J., & Woodruff, A. E. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020947446 · Cited by 4
Kaur, N., Pruthvi, C., & Rohit, M. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00152-x · Cited by 4
Niereninsuffizienz im Kontext der kardiopulmorenalen Pathophysiologie
Schwenger, V., Emrich, I. E., Mahfoud, F., Latus, J., & Remppis, A. (2021) · Der Internist · doi:10.1007/s00108-021-01170-2 · Cited by 4
Recently Approved and Under Investigation Drugs for Treating Patients with Heart Failure
Torres, Y. C., & Katholi, R. E. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180702151626 · Cited by 6
Increasing Complexity of Heart Failure Therapy Requires Earlier and More Frequent Referral
Lund, L. H. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.04.015 · Cited by 4
The Weight of Evidence for Diuretics and Parachutes
Cox, Z. L., & Stevenson, L. W. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.044 · Cited by 4
Heart Failure and Chronic Kidney Disease Patients
Rossignol, P., & Pitt, B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.027 · Cited by 4
Drawing Boundaries around PARADISE
Stevenson, L. W., & DeFilippis, A. P. (2021) · New England Journal of Medicine · doi:10.1056/nejme2115471 · Cited by 4
Early SGLT2 Inhibitors in Acute Heart Failure
Costanzo, M. R., & Januzzi, J. L. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.012 · Cited by 4
Nishikimi, T., Nakagawa, Y., Miyamoto, S., Kanamori, T., Inazumi, H., Yanagisawa, H., Moriuchi, K., Kinoshita, H., Tamamura, Y., Takahama, H., et al. (2025) · Open Heart · doi:10.1136/openhrt-2024-002990 · Cited by 3
Nagy, D., Radovits, T., Bálint, T., Horváth, Z., Kocsis‐Balogh, P., Tóth, Á. G., Oláh, A., Sayour, A. A., Barta, B. A., Merkely, B. P., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70250 · Cited by 4
López‐López, A., Regueiro‐Abel, M., Johk-Casas, C. A., Viéitez-Flórez, J. M., Elices‐Teja, J., Rivas, J. A., Seara, G. D. U., López-Pena, A. M., Álvarez-Suárez, C. C., Rois-González, G., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15030991 · Cited by 3
Contemporary Management of Acute Heart Failure
Bruno, J., Arrigo, M., Baudry, G., Biegus, J., Bozkurt, B., Čerlinskaitė‐Bajorė, K., COHEN, L. P., Hartshorne‐Evans, N., Ishihara, S., Jessen, N., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.029 · Cited by 5
Correia, E. T. D. O., Barbetta, L. M. D. S., & Mesquita, E. T. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200983 · Cited by 6
Fang, X., Song, R., Wei, J., Liao, Q., & Zeng, Z. (2022) · Mediators of Inflammation · doi:10.1155/2022/9652169 · Cited by 3
Γιαννόπουλος, Γ., Kousta, M. S., Anagnostopoulos, I., Karageorgiou, S., Myrovali, E., Deftereos, G., Fragakis, N., Siasos, G., & Vassilikos, V. P. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230202141437 · Cited by 4
New insights in acute heart failure
Asakage, A., Mebazaa, A., & Deniau, B. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104184 · Cited by 3
Sachdeva, A., Shukla, A., Mayabhate, M. M., & Kapure, N. (2024) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636241234159 · Cited by 3
Wang, G., Zhang, R., Li, X., Zuo, S., Zhang, B., Zhao, Y., Sun, S., Zhang, J., & Liu, X. (2025) · PeerJ · doi:10.7717/peerj.18873 · Cited by 4
The Rab3 GTPase cycle modulates cardiomyocyte exocytosis and atrial natriuretic peptide release
Essandoh, K., Subramani, A., Koripella, S., & Brody, M. J. (2025) · Biophysical Journal · doi:10.1016/j.bpj.2025.03.013 · Cited by 3
Echeverría, L. E., Rojas, L. Z., García, A. Y. S., Botero, D., García-Rueda, K. A., Torres-Bustamante, A. M., Cañón‐Gómez, D. I., Salcedo, J. S., Hurtado‐Ortiz, A., Rodriguez‐Canales, J., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15286 · Cited by 4
Ye, L., Chang, A. J., Chioncel, O. D., Antohi, E., Geavlete, O. D., Abdelhamid, M., Adamo, M., Biegus, J., Chopra, V., Cotter, G., et al. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10515-0 · Cited by 3
Self-citationLido, P., Cantiero, S., Galluccio, A., Noce, A., Lullo, L. D., Bei, R., Iellamo, F., Mannucci, P. M., Nobili, A., Tettamanti, M., et al. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04026-x · Cited by 3
Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure
Tymińska, A., Ozierański, K., Grabowski, M., Opolski, G., & Balsam, P. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0094 · Cited by 3
Choi, I. J., Lim, S., Hwang, Y., Lee, D., Lee, W. J., Lee, K. Y., Kim, M.-J., & Jeon, D. S. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01636-5 · Cited by 3
Effects of sacubitril/valsartan in patients with left ventricular assist devices: Case series
Žorž, N., Frljak, S., & Vrtovec, B. (2020) · Artificial Organs · doi:10.1111/aor.13796 · Cited by 3
Cheng, S., Zhang, N., & Hua, W. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00448-4 · Cited by 3
Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research
Cotter, G., Davison, B. A., Mebazaa, A., Takagi, K., Novosadova, M., Freund, Y., & Solal, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091803 · Cited by 3
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury
Lee, S., Hwang, H.-S., Song, N., Kang, G.-H., Choi, K., Ji, E., Song, J., & Kang, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168598 · Cited by 3
Sacubitril/Valsartan: The Role of Neprilysin Pathway in Heart Failure
Laksono, S., Angelia, F., & Prawara, A. S. (2021) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2021.10.2.133 · Cited by 4
ARNI in HFrEF—One-Centre Experience in the Era before the 2021 ESC HF Recommendations
Niemiec, R., Morawska, I., Stec, M., Kuczmik, W., Swinarew, A. S., Stanula, A., & Mizia‐Stec, K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042089 · Cited by 5
Lin, P., Lee, Y., Liu, L. Y., Tsai, C., Yang, T.-F., Chiou, W., Hsieh, M., Chang, H., & Huang, C. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221107799 · Cited by 3
Butler, J., Siddiqi, T. J., & Anker, S. D. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2684 · Cited by 3
Araujo, F. G., & Ramos, R. R. (2022) · Journal of Modern Medicinal Chemistry · doi:10.12970/2308-8044.2022.10.02 · Cited by 3
der Linden, L. R. V., Hias, J., Walgraeve, K., Tournoy, J., Aelst, L. N. L. V., & Vandenbriele, C. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00987-2 · Cited by 3
Setoguchi, N., Horiuchi, Y., Kawakami, T., Nakase, M., Watanabe, Y., Ishizawa, T., Sekiguchi, M., Nakajima, M., Nonaka, H., Asami, M., et al. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02253-w · Cited by 3
A Retrospective Analysis of Sacubitril/Valsartan in Heart Failure and Chronic Kidney Disease
McFarland, K. L., & Sheridan, E. A. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225231168543 · Cited by 4
Jain, A., MEYUR, S., Wadhwa, L., Singh, K., Sharma, R., Panchal, I., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.41566 · Cited by 3
Park, H. K., Park, J. S., Kim, M. S., Lee, E., Choi, H., Park, Y. J., Park, B. E., Kim, H. N., Kim, N., Bae, M. H., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14505 · Cited by 2
Khan, M. S., Rashid, A. M., Shafi, T., Ferreira, J. P., & Butler, J. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151429 · Cited by 5
Reyaz, I., Kaur, A., Saad, M. Z., Kanumuri, M., Nistala, H. P., Usman, S., Olivas, C., & Palleti, S. K. (2023) · Cureus · doi:10.7759/cureus.48623 · Cited by 3
Ji, Q. (2023) · Clinical Cardiology · doi:10.1002/clc.24192 · Cited by 4
Chronic heart failure with reduced EF: A decade of major pharmacological innovations
Trochu, J. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104219 · Cited by 4
Wu, A., Lin, Z., Yang, Z., Zhang, H., Hu, J., Yi, W. A. N. G., Rui, T. A. N. G., Zhang, X., Ji, X., & Lu, H. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.12.005 · Cited by 3
Use of sacubitril/valsartan early after CABG
Нуржанова, М. А., Musagaliyeva, A., Zhakypova, R., Senkibayeva, D., & Rakisheva, A. (2024) · Open Heart · doi:10.1136/openhrt-2023-002492 · Cited by 7
How to Change the Medical History of Patients with Heart Failure and Recurrent Hospitalizations?
Andrade, F. A., Monferdini, L., & Vieira, J. L. (2023) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230092 · Cited by 3
State of the art on angiotensin-neprilysin inhibitors
Sunkara, A., Campbell, P. T., Ventura, H. O., & Krim, S. R. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06500-1 · Cited by 3
Alsohimi, S., Almagthali, A., Mandar, D., Ghandourah, F., AlButi, H., Alshehri, S. O., Aljabri, A. M., & Alshibani, M. (2024) · Medicine · doi:10.1097/md.0000000000038960 · Cited by 4
Zhao, S., He, R., Mei, M., Yu, M., Yang, Z., Tian, C., Zhang, P., & Li, R. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001639 · Cited by 3
Srivastava, P. K., Klomhaus, A. M., Greene, S. J., Heidenreich, P. A., Lewsey, S. C., Yancy, C. W., & Fonarow, G. C. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3815 · Cited by 3
Takahashi, T., Kusunose, K., Imai, T., Furukawa, Y., Okada, T., Kadokami, T., Kanzaki, Y., Matsuda, H., Mizukoshi, K., Kida, K., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf061 · Cited by 4
Iacovoni, A., D’Elia, E., Gori, M., Oliva, F. G., Lorini, F. L., & Senni, M. (2019) · Cardiac failure review · doi:10.15420/cfr.2018.46.2 · Cited by 4
Ambrosy, A. P., Fudim, M., & Chioncel, O. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1555 · Cited by 3
Self-citationThe Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction
Ovchinnikov, A. G., Gvozdeva, A. D., Николаевна, Б. З., Borisov, A. A., & Ageev, F. T. (2020) · Kardiologiia · doi:10.18087/cardio.2020.11.n1352 · Cited by 3
Fong, M., Chang, H. Y., Wang, C. C., Feng, A. N., Lin, W. S., Wu, Y., Sung, S., Huang, J. L., Kuo, J. Y., & Yin, W. H. (2021) · PubMed Central · doi:10.6515/acs.202107_37(4).20201223a · Cited by 4
ABCs of Heart Failure Management: A Guide for Nurse Practitioners
Hussein, M. T. E., Blayney, S., & Clark, N. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2019.12.021 · Cited by 5
Zyryanov, S. K., & Ушкалова, Е. А. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-1-3690 · Cited by 4
Lang, K., Iterson, E. H. V., & Laffin, L. J. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00203-5 · Cited by 3
Jędrzejewska, A., Braczko, A., Kawecka, A., Hellmann, M., Siondalski, P., Slominska, E. M., Kutryb-Zając, B. A., Yacoub, M. H., & Smolenski, R. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179886 · Cited by 3
Natriuretic Peptides as a Surrogate Endpoint in Clinical Trials — a Riddle Wrapped in an Enigma
Hardwick, A. B., & Ambrosy, A. P. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1448 · Cited by 3
Self-citationLong-Term Outcomes According to Etiology May Alter Under Different Circumstances
Shoji, S., Shiraishi, Y., Kohsaka, S., Fukuda, K., & Yoshikawa, T. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.08.021 · Cited by 3
Warren, P. F. (2009) · ProQuest LLC eBooks · Cited by 4
Urinary NGAL in acute heart failure revisited: the game is not over yet
Aimo, A., Lupón, J., Bayés‐Genís, A., & Emdin, M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.023 · Cited by 4
Galati, G., Андреевна, Г. О., Pedretti, R. F. E., & Ambrosio, G. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131118 · Cited by 4
(2024) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2024.19.s1 · Cited by 3
How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?
Gilstrap, L. G., & Vest, A. R. (2022) · NEJM Evidence · doi:10.1056/evidccon2200084 · Cited by 2
Metadata
- Authors
- Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-07
- Volume
- 380
- Issue
- 6
- Pages
- 539-548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899841238
- Cited by
- 1,260
- References
- 16
- Citations by year
- 2026: 74 · 2025: 139 · 2024: 136 · 2023: 215 · 2022: 199 · 2021: 189 · 2020: 171 · 2019: 128
- FWCI
- 93.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- acute decompensated heart failure, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, NT-proBNP, renal function, hyperkalemia, angioedema, symptomatic hypotension, drug safety, hospitalization, hemodynamic stabilization, natriuretic peptides
- MeSH terms
- Valsartan, Acute Disease, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiac Output, Low, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Stroke Volume, Tetrazoles, Neprilysin, Natriuretic Peptide, Brain, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.